News
BIOA
10.79
+2.96%
0.31
Weekly Report: what happened at BIOA last week (0803-0807)?
Weekly Report · 3d ago
BioAge Labs price target lowered to $20 from $23 at Morgan Stanley
TipRanks · 6d ago
Analysts’ Opinions Are Mixed on These NA Stocks: BioAge Labs, Inc. (BIOA) and Fiserv (FISV)
TipRanks · 6d ago
Oppenheimer Sticks to Its Buy Rating for BioAge Labs, Inc. (BIOA)
TipRanks · 08/06 13:07
BioAge Labs: Upstream NLRP3 Strategy and Strong Cash Runway Underpin Unchanged $35 Price Target and Buy Rating
TipRanks · 08/06 12:25
Analysts Are Bullish on These NA Stocks: BillionToOne, Inc. Class A (BLLN), Carlsmed, Inc. (CARL)
TipRanks · 08/06 11:11
Andy Hsieh Reiterates Hold on BioAge as Strong Cash Runway Offsets Execution and Clinical Surrogate Uncertainties
TipRanks · 08/06 01:45
BioAge Labs reports Q2 EPS (58c), consensus (62c)
TipRanks · 08/05 23:00
BioAge Labs GAAP EPS of -$0.58 beats by $0.03, revenue of $2.45M beats by $0.95M
Seeking Alpha · 08/05 22:02
BioAge Labs, Inc. (BIOA) Gets a Buy from Piper Sandler
TipRanks · 08/05 07:05
BioAge Labs' Longevity Data Look Promising, but the Market Still Wants Revenue
Barchart · 08/04 16:05
Analysts Offer Insights on NA Companies: Central Bancompany (CBC) and BioAge Labs, Inc. (BIOA)
TipRanks · 08/03 13:20
Weekly Report: what happened at BIOA last week (0727-0731)?
Weekly Report · 08/03 10:21
Analysts Have Conflicting Sentiments on These NA Companies: BioAge Labs, Inc. (BIOA) and adidas AG (GB:0OLD)
TipRanks · 08/01 09:00
Roth MKM Reaffirms Their Buy Rating on BioAge Labs, Inc. (BIOA)
TipRanks · 07/31 18:55
Monte Rosa, BioAge sink following Novo Nordisk’s ZEUS setback
TipRanks · 07/31 18:50
BioAge Labs price target lowered to $25 from $36 at Roth Capital
TipRanks · 07/31 18:40
BioAge Therapeutics: Buy Rating Maintained Despite Cut in Price Target to $21 on Refined ASCVD and Ocular Program Assumptions
TipRanks · 07/31 18:36
Buy Rating Reaffirmed on BioAge: Sell-Off Seen as Overdone Amid Validated NLRP3 Platform and Triple-Digit Upside Potential
TipRanks · 07/31 18:36
Monte Rosa, BioAge plunge as Novo’s setback casts a shadow over pipeline
Seeking Alpha · 07/31 18:09
More
Webull provides a variety of real-time BIOA stock news. You can receive the latest news about BioAge Labs Inc. through multiple platforms. This information may help you make smarter investment decisions.
About BIOA
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.